title: New pharmacologic treatments for familial hypercholesterolemia.
abstract: Familial hypercholesterolemias are a group of genetic disorders that cause high levels of low-density lipoprotein (LDL) cholesterol, which can lead to atherosclerosis and premature coronary heart disease. Heart disease is the leading cause of death in U.S. women. A major goal in prevention of cardiovascular disease is identification and modification of risk factors. Lomitapide and mipomersen are two new pharmacologic options for treatment of familial hypercholesterolemia. Both are indicated as an adjunct for the management of homozygous familial hypercholesterolemia, along with lipid-lowering medications and diet modification.
authors.forename: Annette
authors.initials: A
authors.lastname: McDonough
authors.forename: Lea Ann
authors.initials: LA
authors.lastname: Matura
authors.forename: Diane
authors.initials: D
authors.lastname: Carroll
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000494:pharmacology*; D001562:Benzimidazoles / Q000009:adverse effects / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000145:classification; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy*; D009841:Oligonucleotides / Q000009:adverse effects / Q000494:pharmacology*; D010353:Patient Education as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D012307:Risk Factors; D012308:Risk Management; D040242:Risk Reduction Behavior; D014481:United States; D016387:Women's Health
chemical_list: D000924:Anticholesteremic Agents; C473731:BMS201038; D001562:Benzimidazoles; D009841:Oligonucleotides; C524142:mipomersen
keywords: LDL; cholesterol; familial hypercholesterolemia; lomitapide; mipomersen